Pathogenesis and therapeutic implications of cardiorenal syndrome

Clinical and Experimental Nephrology

Volumn 15, Issue 2, 2011, Pages 187-194

  Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anemia; Cardiorenal syndrome; Chronic kidney disease; Heart failure; Rennin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ARGIPRESSIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEUROHORMONE; NITRIC OXIDE; NORADRENALIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DIURESIS; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HOMEOSTASIS; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL DECISION MAKING; MORTALITY; NATRIURESIS; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT INFORMATION; PLASMA RENIN ACTIVITY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SUDDEN DEATH; SYSTEMIC VASCULAR RESISTANCE; TISSUE OXYGENATION; TISSUE PERFUSION; TREATMENT PLANNING; ULTRAFILTRATION;

ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SYNDROME;

EID: 79959187462     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0374-0     Document Type: Review

References (70)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69.
2. Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16:3728-35. (Pubitemid 46211295)
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
4. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95. (Pubitemid 39258422)
5. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228-36. (Pubitemid 43181380)
6. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264-71.
7. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: systematic review. J Am Soc Nephrol. 2006;17:2034-47. (Pubitemid 44036188)
8. Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan. Ther Apher Dial. 2009;13:457-504.
9. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Ide T, Takeshita A, et al. Chronic kidney disease as independent risk factor for long-term adverse outcomes in patients hospitalized with heart failure in Japan: report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1442-7.
10. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16.
11. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987-96.
12. Longhini C, Molino C, Fabbian F. Cardiorenal syndrome: still not a defined entity. Clin Exp Nephrol. 2010;14:12-21.
13. McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med. 2010;122:25-34.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-266.
15. McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens. 2004;13:591-600. (Pubitemid 39506906)
16. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225-32. (Pubitemid 35463925)
17. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167:1122-9. (Pubitemid 46919814)
18. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J. 2005;26:11-7.
19. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008;4:47-57. (Pubitemid 350308210)
20. Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51:300-6.
21. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, et al. Cardiorenal interactions: Insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51:1268-74. (Pubitemid 351400890)
22. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116:263-72. (Pubitemid 38224234)
23. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699-706. (Pubitemid 38405571)
24. Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol. 2009;53:639-47.
25. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527-39.
26. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31:703-11.
27. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-41. (Pubitemid 34857278)
28. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-7. (Pubitemid 38045917)
29. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999;138:849-55. (Pubitemid 29523271)
30. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-8. (Pubitemid 38176835)
31. Warren DJ, Ferris TF. Renin secretion in renal hypertension. Lancet. 1970;1:159-62.
32. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R117-24.
33. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA. 2002;99:9450-5. (Pubitemid 34764634)
34. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000;20:645-51. (Pubitemid 30151676)
35. Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III increases MCP-1 and activates NF-kappa B and AP-1 in cultured mesangial and mononuclear cells. Kidney Int. 2000;57:2285-98. (Pubitemid 30340728)
36. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-8. (Pubitemid 23006966)
37. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987-94.
38. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, et al. Cardiac angiotensin II receptors are upregulated by longterm inhibition of nitric oxide synthesis in rats. Circ Res. 1998;83:743-51. (Pubitemid 28462789)
39. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44:959-66. (Pubitemid 39165127)
40. Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ. Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol Regul Integr Comp Physiol. 1995;268:R896-901.
41. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138:917-24. (Pubitemid 38124634)
42. Leier CV. Renal roadblock in managing low output heart failure. Crit Care Med. 2004;32:1228-9. (Pubitemid 38620999)
43. Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Xarson PE, Cropp AB, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31-8. (Pubitemid 34734752)
44. Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol. 1997;80:519-22. (Pubitemid 27371765)
45. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138:285-90. (Pubitemid 29379679)
46. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999;138:849-55. (Pubitemid 29523271)
47. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22. (Pubitemid 17216948)
48. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
49. Geisberg C, Butler J. Addressing the challenges of cardiorenal syndrome. Cleve Clin J Med. 2006;73:485-91.
50. Echemann M, Zannad F, Briancon S, Hulliere Y, Mertes PM, Virion JM, et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J. 2000;139:624-31. (Pubitemid 30207787)
51. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70:479-87.
52. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-64.
53. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994; 93:2578-83. (Pubitemid 24177174)
54. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. (Pubitemid 29407370)
55. Pitt B, Remme W, Zannad F, NNeaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21. (Pubitemid 36384098)
56. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/ enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-8. (Pubitemid 37296092)
57. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004; 93:990-6. (Pubitemid 38479452)
58. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006; 119:912-9. (Pubitemid 44634312)
59. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003;14:2395-401. (Pubitemid 37052388)
60. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641-50.
61. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:542-51.
62. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-47.
63. Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004;43:649-59. (Pubitemid 39264162)
64. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-44. (Pubitemid 30342851)
65. Cleveland JG, Sullivan JT, Ball S, Horowitz JD, Agoram B, Rosser D, et al. Once-monthly administration of darbopoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol. 2005;46:155-61. (Pubitemid 41060207)
66. Ghali K, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al. Randomized double-blind trial of darbopetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526-35.
67. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease. N Engl J Med. 2006;355:2071-84. (Pubitemid 44749316)
68. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98. (Pubitemid 44749317)
69. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-83. (Pubitemid 46205043)
70. Rogers HL, Marshall J, Bock J, Dowling TC, Feller E, Robinson S, et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. 2008;4:1-5.